Critical Contrast: ALGAE TEC LTD/S (OTCMKTS:ALGXY) & Pieris Pharmaceuticals (OTCMKTS:PIRS)

Share on StockTwits

ALGAE TEC LTD/S (OTCMKTS:ALGXY) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Risk and Volatility

ALGAE TEC LTD/S has a beta of 65.48, meaning that its share price is 6,448% more volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for ALGAE TEC LTD/S and Pieris Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ALGAE TEC LTD/S 0 0 0 0 N/A
Pieris Pharmaceuticals 0 0 3 0 3.00

Pieris Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 38.25%. Given Pieris Pharmaceuticals’ higher probable upside, analysts clearly believe Pieris Pharmaceuticals is more favorable than ALGAE TEC LTD/S.

Institutional & Insider Ownership

59.7% of Pieris Pharmaceuticals shares are owned by institutional investors. 6.6% of Pieris Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares ALGAE TEC LTD/S and Pieris Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
ALGAE TEC LTD/S N/A N/A N/A
Pieris Pharmaceuticals -84.75% -64.64% -19.37%

Valuation & Earnings

This table compares ALGAE TEC LTD/S and Pieris Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ALGAE TEC LTD/S $2.05 million N/A -$6.08 million N/A N/A
Pieris Pharmaceuticals $29.10 million 7.33 -$26.75 million ($0.50) -8.68

ALGAE TEC LTD/S has higher earnings, but lower revenue than Pieris Pharmaceuticals.

ALGAE TEC LTD/S Company Profile

Affinity Energy and Health Limited operates as a plant-based health and wellbeing company in Australia, India, and the United States. It engages in developing technology to produce commercial quantities of algae and medicinal cannabis for supply to algae-based nutraceuticals, animal feed and aquaculture, medicinal cannabis, and biofuels markets. The company offers FeedMe Algae, an algae-based aqua feed; and algae-based biofuels. Affinity Energy and Health Limited was founded in 2007 and is based in Subiaco, Australia.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company is also developing PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., and Sanofi, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Receive News & Ratings for ALGAE TEC LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALGAE TEC LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.